These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 33840206)

  • 21. Sustained responses to lasmiditan: Results from post-hoc analyses of two Phase 3 randomized clinical trials for acute treatment of migraine.
    Doty EG; Krege JH; Jin L; Raskin J; Halker Singh RB; Kalidas K
    Cephalalgia; 2019 Oct; 39(12):1569-1576. PubMed ID: 31266353
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Profiling lasmiditan as a treatment option for migraine.
    Curto M; Cipolla F; Cisale GY; Capi M; Spuntarelli V; Guglielmetti M; Martelletti P; Lionetto L
    Expert Opin Pharmacother; 2020 Feb; 21(2):147-153. PubMed ID: 31766908
    [No Abstract]   [Full Text] [Related]  

  • 23. Onset of Efficacy Following Oral Treatment With Lasmiditan for the Acute Treatment of Migraine: Integrated Results From 2 Randomized Double-Blind Placebo-Controlled Phase 3 Clinical Studies.
    Ashina M; Vasudeva R; Jin L; Lombard L; Gray E; Doty EG; Yunes-Medina L; Kinchen KS; Tassorelli C
    Headache; 2019 Nov; 59(10):1788-1801. PubMed ID: 31529622
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Serotonin receptor targeted therapy for migraine treatment: an overview of drugs in phase I and II clinical development.
    Barbanti P; Aurilia C; Egeo G; Fofi L; Palmirotta R
    Expert Opin Investig Drugs; 2017 Mar; 26(3):269-277. PubMed ID: 28103158
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase 2 randomized placebo-controlled study of lasmiditan for the acute treatment of migraine in Japanese patients.
    Sakai F; Takeshima T; Homma G; Tanji Y; Katagiri H; Komori M
    Headache; 2021 May; 61(5):755-765. PubMed ID: 33990951
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The selective 5-HT
    Vila-Pueyo M; Page K; Murdock PR; Loraine HJ; Woodrooffe AJ; Johnson KW; Goadsby PJ; Holland PR
    Br J Pharmacol; 2022 Feb; 179(3):358-370. PubMed ID: 34600443
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Profile of Lasmiditan in the Acute Treatment of Migraine in Adults: Design, Development, and Place in Therapy.
    Anderson CC; VanderPluym JH
    Drug Des Devel Ther; 2023; 17():1979-1993. PubMed ID: 37426628
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Characterization of binding, functional activity, and contractile responses of the selective 5-HT
    Rubio-Beltrán E; Labastida-Ramírez A; Haanes KA; van den Bogaerdt A; Bogers AJJC; Zanelli E; Meeus L; Danser AHJ; Gralinski MR; Senese PB; Johnson KW; Kovalchin J; Villalón CM; MaassenVanDenBrink A
    Br J Pharmacol; 2019 Dec; 176(24):4681-4695. PubMed ID: 31418454
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of 2-Hour Post-Dose Efficacy of Lasmiditan for the Acute Treatment of Difficult-to-Treat Migraine Attacks.
    Tepper SJ; Vasudeva R; Krege JH; Rathmann SS; Doty E; Vargas BB; Magis D; Komori M
    Headache; 2020 Sep; 60(8):1601-1615. PubMed ID: 32634275
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tolerability and Safety of Lasmiditan Treatment in Elderly Patients With Migraine: Post Hoc Analyses From Randomized Studies.
    Martin VT; Ahmed Z; Hochstetler HM; Baygani SK; Dong Y; Hauck PM; Khanna R
    Clin Ther; 2021 Jun; 43(6):1066-1078. PubMed ID: 34366152
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lasmiditan for Acute Treatment of Migraine in Adults: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
    Yang Y; Sun Y; Gao B; Wang Z; Chen Z; Wang Z
    CNS Drugs; 2020 Oct; 34(10):1015-1024. PubMed ID: 32857291
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lasmiditan efficacy in the acute treatment of migraine was independent of prior response to triptans: Findings from the CENTURION study.
    Reuter U; Krege JH; Lombard L; Gomez Valderas E; Krikke-Workel J; Dell-Agnello G; Dowsett SA; Buse DC
    Cephalalgia; 2022 Jan; 42(1):20-30. PubMed ID: 34644189
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of a rescue or recurrence dose of lasmiditan on efficacy and safety in the acute treatment of migraine: findings from the phase 3 trials (SAMURAI and SPARTAN).
    Loo LS; Plato BM; Turner IM; Case MG; Raskin J; Dowsett SA; Krege JH
    BMC Neurol; 2019 Aug; 19(1):191. PubMed ID: 31409292
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Neuropsychiatric Safety Profile of Lasmiditan: A Comparative Disproportionality Analysis with Triptans.
    Merino D; Gérard AO; Van Obberghen EK; Destere A; Lanteri-Minet M; Drici MD
    Neurotherapeutics; 2023 Sep; 20(5):1305-1315. PubMed ID: 37436579
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lasmiditan for the treatment of migraine.
    Capi M; de Andrés F; Lionetto L; Gentile G; Cipolla F; Negro A; Borro M; Martelletti P; Curto M
    Expert Opin Investig Drugs; 2017 Feb; 26(2):227-234. PubMed ID: 28076702
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lasmiditan Is a New Option for Acute Migraine Treatment.
    Blakely KK; Stallworth K
    Nurs Womens Health; 2020 Aug; 24(4):294-299. PubMed ID: 32663443
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Randomized, controlled trial of lasmiditan over four migraine attacks: Findings from the CENTURION study.
    Ashina M; Reuter U; Smith T; Krikke-Workel J; Klise SR; Bragg S; Doty EG; Dowsett SA; Lin Q; Krege JH
    Cephalalgia; 2021 Mar; 41(3):294-304. PubMed ID: 33541117
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and Safety of Lasmiditan for Acute Treatment of Migraine in Adults: A Meta-Analysis.
    Maiti R; Mishra A; Puliappadamb HM; Jena M; Srinivasan A
    J Clin Pharmacol; 2021 Dec; 61(12):1534-1544. PubMed ID: 34472095
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term treatment with lasmiditan in patients with migraine: post hoc analysis of treatment patterns and outcomes from the open-label extension of the CENTURION randomized trial.
    Komori M; Ozeki A; Tanji Y; Kamiki E; Krege JH; Li LQ; Suzuki S; Shibata M; Takeshima T
    J Headache Pain; 2024 Mar; 25(1):43. PubMed ID: 38528476
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of a change in lasmiditan dose on efficacy and safety in patients with migraine.
    Clemow DB; Hochstetler HM; Dong Y; Hauck P; Peres MFP; Ailani J
    Postgrad Med; 2021 May; 133(4):449-459. PubMed ID: 33730977
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.